Page last updated: 2024-11-05

ioglycamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ioglycamic acid is an organic compound used as a contrast agent in medical imaging, particularly for X-ray examinations of the gastrointestinal tract. It is a diatrizoic acid derivative, and its synthesis involves the reaction of diatrizoic acid with an appropriate amine, followed by purification and formulation. Ioglycamic acid works by increasing the density of the targeted tissues, making them more visible on X-ray images. It is administered orally or rectally, and its effects are typically temporary. The study of ioglycamic acid is important for its role in diagnosing and monitoring various gastrointestinal conditions, such as ulcers, polyps, and tumors. It is also used to assess the function of the digestive system and to identify potential abnormalities.'

Ioglycamic Acid: A radiopaque medium. It is a mixture of its meglumine and sodium salts and is used to visualize the biliary tract. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17477
CHEMBL ID2106372
CHEBI ID135902
SCHEMBL ID433485
MeSH IDM0011671

Synonyms (44)

Synonym
ioglycamic acid
ioglycamic acid (usan/inn)
D04577
2618-25-9
CHEBI:135902
3-[[2-[2-(3-carboxy-2,4,6-triiodoanilino)-2-oxoethoxy]acetyl]amino]-2,4,6-triiodobenzoic acid
ioglycamid
acido ioglicamico
ioglycamide
be 419
acidum joglycamicum
sh 419
et36gpp4t7 ,
acidum ioglycamicum
unii-et36gpp4t7
n,n'-oxydiacetyl-bis-(3-amino-2,4,6-triiodbenzoesaeure
benzoic acid, 3,3'-(oxybis((1-oxo-2,1-ethanediyl)imino))bis(2,4,6-triiodo-
acidum ioglycamicum [inn-latin]
acido ioglicamico [inn-spanish]
3,3'-(diglycoloyldiimino)bis(2,4,6-triiodobenzoic acid)
acide ioglycamique [inn-french]
acide ioglycamique
ioglycamic acid [usan:inn:ban]
einecs 220-048-8
ioglycaminsaeure
be-419
CHEMBL2106372
FT-0627275
ioglycamic acid [mi]
ioglycamic acid [inn]
ioglycamic acid [usan]
ioglycamic acid [mart.]
ioglycamic acid [who-dd]
benzoic acid, 3,3'-(oxybis((1-oxo-2,1-ethanediyl)imino))bis(2,4,6-triiodo)-
SCHEMBL433485
AKOS022146490
MLS006011720
smr002530506
benzoic acid,3,3'-[oxybis[(1-oxo-2,1-ethanediyl)imino]]bis[2,4,6-triiodo-
DTXSID50180801
SR-01000945267-1
sr-01000945267
Q6062359
DB13741

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It is shown that slow and constant injection leads to a decrease in the rate of adverse reactions and improvement of radiographic demonstration."( [Injection cholecystography--influence of radiopaque substance and injection time on the excretion of contrast media and incidence of side effects].
Schmerwitz, W, 1977
)
0.26
" The intravenous biliary contrast medium--ioglycamate--was most toxic to all cell types."( Toxicity of X-ray contrast media in cell cultures.
Frey, H; Kormano, M,
)
0.13

Dosage Studied

ExcerptRelevanceReference
"In the anaesthetized pig we studied the influence of the dosage of the contrast medium Iotroxinate on the following parameters of bile secretion: bile flow, bile salt excretion, concentration, and excretion of Iotroxinate."( [Dose-effects of the contrast medium Iotroxinate on biliary excretion of contrast media during infusion cholegraphy (author's transl)].
Klapdor, R, 1978
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amidobenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-199092 (94.85)18.7374
1990's5 (5.15)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.40 (24.57)
Research Supply Index4.87 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (11.21%)5.53%
Reviews4 (3.45%)6.00%
Case Studies2 (1.72%)4.05%
Observational0 (0.00%)0.25%
Other97 (83.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]